PTPN11 and acute myeloid leukemia: As said, monocytic AML cells are able to increase OXPHOS, and RAS- and PTPN11-mutated AML cells are able to use fatty acid metabolism and glycolysis to compensate for low OXPHOS and low amino acid levels, thereby reducing sensitivity to venetoclax [97,98,100].